- Zyesami or aviptadil is an application for COVID-related respiratory failure that has reached an advanced stage in clinical trials.
- It is being developed by NRx Pharmaceuticals, in commercial partnership with Switzerland's Relief Therapeutics covering funding of certain clinical aspects of development in return for profits.
- Investors appear to have been spooked after Relief filed a lawsuit against NRx where there is mention of damages.
- Nonetheless, the partners' main therapeutic asset remains significant in light of fluctuating hospitalization rates, and they are both diversified in other therapies.
- Looking at the way the market has been punishing both companies' stocks after August highs suggests that it would be better to wait on the sidelines for concrete corporate updates before investing.
For further details see:
NRx And Relief: Avoid Buying The Dips